Opaleye Management Buys More Alpha Cognition Shares Amid Low Prices, Signals Long‑Term Confidence.

Insider Buying at Alpha Cognition Signals Confidence Amid a Volatile Season

On September 14, 2026, Opaleye Management Inc. added roughly 40 000 shares of Alpha Cognition Inc. to its portfolio, paying a weighted‑average price of $8.70. The transaction, announced via Form 4, comes at a time when the stock is trading near its 52‑week low of $4.50 and has seen an 8 % decline over the past week. Despite the recent slide, the buy is noteworthy because it follows a steady stream of purchases by the same investment manager over the past two months, in which it has steadily increased its stake from about 2.7 million shares in early July to over 3.1 million shares today. The cumulative buying spree—roughly 280 000 shares at an average of $6.80—indicates that Opaleye remains bullish on Alpha Cognition’s long‑term prospects, even as the share price continues to dip.

What This Means for Investors

The recent purchase is a subtle but positive signal. Alpha Cognition’s core business—development of oral neuro‑psychiatric therapeutics—has been under pressure as the company’s quarterly earnings have missed estimates, and its price‑to‑earnings ratio sits at a negative –5.57, reflecting ongoing losses. In such an environment, new insider buying can suggest that the company’s management or its institutional investors believe that the current valuation is a buying opportunity. For the broader investor base, Opaleye’s continued accumulation could be interpreted as a “buy the dip” play, potentially providing a floor for the stock if the company can navigate its upcoming clinical milestones. Conversely, the persistent volatility and the fact that the market has not yet rebounded from the recent 8 % weekly decline mean that caution is warranted; a single transaction may not override broader market sentiment.

Opaleye Management’s Historical Buying Pattern

Opaleye Management Inc. has a disciplined, incremental approach to building positions in Alpha Cognition. From early July to mid‑September, the fund purchased between 1,500 and 150,000 shares per transaction, always at a price slightly above the prevailing market level. The average entry price over this period hovers around $6.80, significantly below the current $8.80 close. This pattern suggests a long‑term view: the fund is buying through market noise, not in reaction to short‑term price swings. The firm’s holdings have grown steadily, from about 2.7 million shares in early July to 3.1 million by mid‑September—a 15 % increase in ownership. In addition, Opaleye’s other holdings in the company remain unchanged at 100 000 shares, indicating that the fund is primarily focusing on incremental accumulation rather than diversification within the firm.

Implications for Alpha Cognition’s Future

The sustained insider buying by Opaleye comes at a pivotal juncture for Alpha Cognition. The company is poised to release data from its Phase 2 study on its oral brexanolone candidate, which could either validate its pipeline or exacerbate the current earnings shortfall. If the data are favorable, the share price could recover, amplifying the value of Opaleye’s position. Even if the results are mixed, the firm’s existing pipeline and strategic partnerships give it a credible trajectory for growth. For investors, Opaleye’s confidence should be weighed against the company’s negative earnings outlook and the broader market’s sensitivity to health‑care earnings. Nonetheless, the pattern of incremental buying—combined with a significant stake and a history of long‑term holding—suggests that Opaleye Management sees Alpha Cognition’s valuation as undervalued relative to its pipeline potential.

Bottom Line

Opaleye Management’s recent purchase, part of a larger trend of incremental buying, signals a belief that Alpha Cognition’s current valuation is a bargain. For shareholders, this could translate into a supportive floor for the stock if the company’s clinical milestones materialize. However, the lingering volatility and negative earnings profile mean that investors should monitor the company’s clinical progress and earnings guidance closely before committing.